Literature DB >> 11739732

Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation.

Martin O Bergo1, Patricia Ambroziak, Cria Gregory, Amanda George, James C Otto, Edward Kim, Hiroki Nagase, Patrick J Casey, Allan Balmain, Stephen G Young.   

Abstract

After isoprenylation, the Ras proteins and other CAAX proteins undergo two additional enzymatic modifications-endoproteolytic release of the last three amino acids of the protein by the protease Rce1 and methylation of the carboxyl-terminal isoprenylcysteine by the methyltransferase Icmt. This postisoprenylation processing is thought to be important for the association of Ras proteins with membranes. Blocking postisoprenylation processing, by inhibiting Rce1, has been suggested as a potential approach for retarding cell growth and blocking cellular transformation. The objective of this study was to develop a cell culture system for addressing these issues. We generated mice with a conditional Rce1 allele (Rce1(flox)) and produced Rce1(flox/flox) fibroblasts. Cre-mediated excision of Rce1 (thereby producing Rce1(Delta/Delta) fibroblasts) eliminated Ras endoproteolytic processing and methylation and caused a partial mislocalization of truncated K-Ras and H-Ras fusion proteins within cells. Rce1(Delta/Delta) fibroblasts grew more slowly than Rce1(flox/flox) fibroblasts. The excision of Rce1 also reduced Ras-induced transformation, as judged by the growth of colonies in soft agar. The excision of Rce1 from a Rce1(flox/flox) skin carcinoma cell line also significantly retarded the growth of cells, and this effect was exaggerated by cotreatment of the cells with a farnesyltransferase inhibitor. These studies support the idea that interference with postisoprenylation processing retards cell growth, limits Ras-induced transformation, and sensitizes tumor cells to a farnesyltransferase inhibitor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11739732      PMCID: PMC134215          DOI: 10.1128/MCB.22.1.171-181.2002

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  38 in total

1.  A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane.

Authors:  J F Hancock; H Paterson; C J Marshall
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

2.  Loss of growth control by TGF-beta occurs at a late stage of mouse skin carcinogenesis and is independent of ras gene activation.

Authors:  S Haddow; D J Fowlis; K Parkinson; R J Akhurst; A Balmain
Journal:  Oncogene       Date:  1991-08       Impact factor: 9.867

Review 3.  Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.

Authors:  J B Gibbs; A Oliff; N E Kohl
Journal:  Cell       Date:  1994-04-22       Impact factor: 41.582

4.  High level expression of mammalian protein farnesyltransferase in a baculovirus system. The purified protein contains zinc.

Authors:  W J Chen; J F Moomaw; L Overton; T A Kost; P J Casey
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

5.  Protein prenylation. Mad bet for Rab.

Authors:  M S Brown; J L Goldstein
Journal:  Nature       Date:  1993-11-04       Impact factor: 49.962

Review 6.  Inhibitors of Ras farnesyltransferases.

Authors:  F Tamanoi
Journal:  Trends Biochem Sci       Date:  1993-09       Impact factor: 13.807

7.  Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.

Authors:  K Kato; A D Cox; M M Hisaka; S M Graham; J E Buss; C J Der
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

8.  The C-terminal polylysine region and methylation of K-Ras are critical for the interaction between K-Ras and microtubules.

Authors:  Z Chen; J C Otto; M O Bergo; S G Young; P J Casey
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

9.  Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.

Authors:  N E Kohl; F R Wilson; S D Mosser; E Giuliani; S J deSolms; M W Conner; N J Anthony; W J Holtz; R P Gomez; T J Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

10.  cDNA cloning and expression of the peptide-binding beta subunit of rat p21ras farnesyltransferase, the counterpart of yeast DPR1/RAM1.

Authors:  W J Chen; D A Andres; J L Goldstein; D W Russell; M S Brown
Journal:  Cell       Date:  1991-07-26       Impact factor: 41.582

View more
  58 in total

1.  Photoaffinity labeling of Ras converting enzyme using peptide substrates that incorporate benzoylphenylalanine (Bpa) residues: improved labeling and structural implications.

Authors:  Kelly Kyro; Surya P Manandhar; Daniel Mullen; Walter K Schmidt; Mark D Distefano
Journal:  Bioorg Med Chem       Date:  2011-10-18       Impact factor: 3.641

2.  Fighting cancer by disrupting C-terminal methylation of signaling proteins.

Authors:  Steven Clarke; Fuyuhiko Tamanoi
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 3.  Protein farnesylation and disease.

Authors:  Giuseppe Novelli; Maria Rosaria D'Apice
Journal:  J Inherit Metab Dis       Date:  2012-02-04       Impact factor: 4.982

Review 4.  Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

Authors:  Adrienne D Cox; Channing J Der; Mark R Philips
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

Review 5.  Posttranslational Modifications of RAS Proteins.

Authors:  Ian Ahearn; Mo Zhou; Mark R Philips
Journal:  Cold Spring Harb Perspect Med       Date:  2018-11-01       Impact factor: 6.915

6.  Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease.

Authors:  Annika M Wahlstrom; Briony A Cutts; Christin Karlsson; Karin M E Andersson; Meng Liu; Anna-Karin M Sjogren; Birgitta Swolin; Stephen G Young; Martin O Bergo
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

7.  Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases.

Authors:  David Michaelson; Wasif Ali; Vi K Chiu; Martin Bergo; Joseph Silletti; Latasha Wright; Stephen G Young; Mark Philips
Journal:  Mol Biol Cell       Date:  2005-01-19       Impact factor: 4.138

Review 8.  Therapeutic intervention based on protein prenylation and associated modifications.

Authors:  Michael H Gelb; Lucas Brunsveld; Christine A Hrycyna; Susan Michaelis; Fuyuhiko Tamanoi; Wesley C Van Voorhis; Herbert Waldmann
Journal:  Nat Chem Biol       Date:  2006-10       Impact factor: 15.040

9.  Inhibition of RAS: proven and potential vulnerabilities.

Authors:  Mariyam Zuberi; Imran Khan; John P O'Bryan
Journal:  Biochem Soc Trans       Date:  2020-10-30       Impact factor: 5.407

Review 10.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.